Provided by Tiger Trade Technology Pte. Ltd.

Tradr 2X Long TEM Daily ETF

33.65
+5.2418.44%
Post-market: 32.91-0.7400-2.20%19:52 EDT
Volume:598.38K
Turnover:18.68M
Market Cap:64.89M
PE:- -
High:33.80
Open:27.28
Low:27.28
Close:28.41
52wk High:152.22
52wk Low:11.52
Shares:1.93M
Float Shares:1.93M
Volume Ratio:1.37
T/O Rate:31.03%
Dividend:3.85
Dividend Rate:11.44%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Guggenheim Reaffirms Their Buy Rating on Tempus AI, Inc. Class A (TEM)

TIPRANKS
·
Jun 01

Tempus AI Price Target Maintained With a $80.00/Share by BTIG

Dow Jones
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM) and Incyte (INCY)

TIPRANKS
·
Jun 01

Tempus AI Launches Next-Generation Agentic AI Platform for Oncology Drug Development

MT Newswires Live
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM)

TIPRANKS
·
Jun 01

Short Report: Tempus AI short interest at record high

TIPRANKS
·
Jun 01

Tempus AI announces launch of PRECISION Challenge for oncology breakthroughs

TIPRANKS
·
May 31

Tempus AI announces introduction of Tempus Preview

TIPRANKS
·
May 31

Tempus AI CEO and Chairman Eric Lefkofsky reports sale of 166,250 common shares worth $7.76 million

Reuters
·
May 30

AI Application Software Shares Extended Gains. Palantir Up 10%; Salesforce And Rubrik Up 8%; Snowflake, GitLab And HubSpot Up 6%

Tiger Newspress
·
May 29

Tempus AI expects 25% top-line growth over next 3 years

TIPRANKS
·
May 29

Tempus AI reiterates FY26 revenue view of $1.59B-$1.6B, consensus $1.59B

TIPRANKS
·
May 29

Tempus AI announces initial results from Multimodal Foundation Model efforts

TIPRANKS
·
May 29

BUZZ-U.S. STOCKS ON THE MOVE-Tempus AI, SOLV Energy, Replimune

Reuters
·
May 29

Tempus AI posts investor day presentation on AI-driven diagnostics, precision-medicine data platform

Reuters
·
May 29

Sector Update: Healthcare

MT Newswires Live
·
May 29

BUZZ-Tempus AI rises after securing FDA approval for tumor test

Reuters
·
May 29

Tempus AI Shares up 7.3% Premarket After FDA Approves Its Xt Cdx Test for Genetic Profiling of Tumors

THOMSON REUTERS
·
May 29

Tempus wins FDA approval for tumor-only label on xT CDx genomic profiling test

Reuters
·
May 29

Tempus Receives FDA Approval for Tumor Only Xt Cdx, Enabling Migration of Its Entire DNA Solid Tumor Portfolio

THOMSON REUTERS
·
May 29